This inventor holds 32 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 17 EPO patents, primarily in Oligonucleotide Design. Top assignees: Roche Innovation Center Copenhagen A/s, Santaris Pharma A/s, Enzon Pharmaceuticals, Inc.. Active years: 1991-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- DK-2610 Roedovre, DK (1991)
- Farum, DK (2004)
- Radovre, DK (2009 - 2010)
- Rødovre, DK (2005 - 2015)
- Roedovre, DK (2016 - 2018)
- Ringsted, DK (2017 - 2019)
- Horsholm, DK (2020)
- Rodovre, DK (2000 - 2021)
- Hørsholm, DK (2023)
Company Filing History:
13 out of 46 
8 out of 44 
3 out of 52 
Years Active: 1991-2023
Areas of Expertise:
Title: Henrik Frydenlund Hansen: Pioneering Innovations in Oligonucleotide Therapeutics
Introduction:
In the realm of innovations and patents, there are exceptional individuals who contribute immensely to the advancement of various fields. One such individual is Henrik Frydenlund Hansen, a prolific inventor from Rødovre, Denmark. With an impressive portfolio of 30 patents, including recent breakthroughs in the field of oligonucleotide therapeutics, Henrik Frydenlund Hansen has made a significant impact on the domain of pharmaceutical science. This article delves into his latest patents, highlights his career accomplishments, explores his collaborations, and showcases the invaluable contributions he has made to the field.
Latest Patents:
Henrik Frydenlund Hansen's recent patents have revolved around developing cutting-edge oligonucleotide technologies, specifically Thiophosphoramidites and Oligonucleotide conjugates. The Thiophosphoramidites patent (patent number XXX) encompasses a novel compound, marked by its formula (II) or (IIb), which finds application in the manufacture of oligonucleotides. This breakthrough offers exciting opportunities for the development of more efficient and effective therapeutic interventions.
Similarly, his Oligonucleotide conjugates patent (patent number XXX) focuses on enhancing the properties of oligonucleotide therapeutics through the use of a cleavable region covalently attached to a conjugate, targeting group, or blocking group. This invention allows for the optimization of the therapeutic index, potentially revolutionizing the field of oligonucleotide-based treatments.
Career Highlights:
Henrik Frydenlund Hansen's career has been marked by notable contributions to some of the most renowned pharmaceutical companies. Previously, he has worked at the Roche Innovation Center Copenhagen A/S, where his expertise and innovative mindset played a pivotal role in driving the company's research and development efforts. Furthermore, his tenure at Santaris Pharma A/S, a Danish biopharmaceutical company specializing in RNA-targeted therapies, demonstrates his influence in advancing oligonucleotide therapeutics.
Collaborations:
In the pursuit of innovation, Henrik Frydenlund Hansen has collaborated with esteemed colleagues, such as Troels Koch and Charlotte Albaek Thrue. These collaborations have fostered a collective ingenuity and shared vision, catalyzing advancements in the field of pharmaceutical science.
Conclusion:
Henrik Frydenlund Hansen's outstanding body of work, including his 30 patents and groundbreaking innovations in the field of oligonucleotide therapeutics, solidifies his position as a visionary inventor. His contributions to the industry and collaborations with fellow experts have undoubtedly shaped the landscape of modern pharmaceutical science. As we continue to explore new horizons in therapeutics, it is innovators like Henrik Frydenlund Hansen who pave the way for transformative breakthroughs, improving the lives of countless individuals worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile